CMOPF (Cosmo NV) Other Stockholders Equity: $11.5 Mil (As of Dec. 2025)


CMOPF Cosmo NV CMOPF
79 GF Score
Price $82.60
GF Value $50.39
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cosmo NV Other Stockholders Equity?

Cosmo NV CMOPF +0.67% 79 Other Stockholders Equity is $11.5 Mil as of Dec. 2025. GuruFocus rates CMOPF with a GF Score™ of 79/100 and a GF Value™ of $50.39 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Cosmo NV's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $11.5 Mil.

Cosmo NV's quarterly Other Stockholders Equity declined from Dec. 2024 ($32.7 Mil) to Jun. 2025 ($9.3 Mil) but then increased from Jun. 2025 ($9.3 Mil) to Dec. 2025 ($11.5 Mil).

Cosmo NV's annual Other Stockholders Equity increased from Dec. 2023 ($32.0 Mil) to Dec. 2024 ($32.7 Mil) but then declined from Dec. 2024 ($32.7 Mil) to Dec. 2025 ($11.5 Mil).

Cosmo NV Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Cosmo NV's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosmo NV Other Stockholders Equity Chart

Cosmo NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.21 46.45 31.95 32.72 11.46

Cosmo NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.95 55.97 32.72 9.33 11.46
CMOPF
79GF Score
Cosmo NV CMOPF
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosmo NV Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $11.5 Mil mean?
Cosmo NV (CMOPF) has a Other Stockholders Equity of $11.5 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Cosmo NV and its competitors.
Is Cosmo NV's Other Stockholders Equity too high?
Cosmo NV's current Other Stockholders Equity is $11.5 Mil. Overall, Cosmo NV has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Other Stockholders Equity compare to LLY and JNJ?
Cosmo NV's Other Stockholders Equity of $11.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Cosmo NV and its competitors. Cosmo NV's current Other Stockholders Equity is $11.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $50.39, compared to a current price of $82.60 — trading 63.9% above its estimated fair value. The current Other Stockholders Equity is $11.5 Mil. Cosmo NV's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Other Stockholders Equity is $11.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosmo NV (CMOPF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued. The current stock price of $82.60 is trading 63.9% above its estimated GF Value™ of $50.39. GuruFocus considers Cosmo NV to be Significantly Overvalued.

Key valuation signals for CMOPF:

  • Other Stockholders Equity: $11.5 Mil
  • GF Value™: $50.39 vs. price of $82.60 (63.9% above fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosmo NV Business Description

Address 91/94 North Wall Quay, 7th Floor, One North Dock, Dublin, IRL, D01 H7V7
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
79GF Score

Get the complete analysis for CMOPF

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$82.60
Price
$50.39
GF Value